Richard A. Heyman
Director at Enliven Therapeutics; Director at ORIC Pharmaceuticals. Based in South San Francisco, California.
- Rank
- 9779th of 14,644
- Companies held
- 2
- Largest holding
- ELVN, 78.5% of total
- Latest SEC filing
- Oct 1, 2026
- Listed but not counted
- $1.2M
What the $8.7M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN Common Stock | Directly | 123,673 | $46.41 | $5.7M | 66.3% | Form 4, Feb 17, 2026 |
| ORIC Pharmaceuticals ORIC Common Stock | Through RAHD Capital, LLC | 203,472 | $7.70 | $1.6M | 18.1% | Form 4, Oct 1, 2026 |
| Enliven Therapeutics ELVN Common Stock | Through Heyman Daigle Trust | 22,647 | $46.41 | $1.1M | 12.1% | Form 4, Feb 17, 2026 |
| ORIC Pharmaceuticals ORIC Common Stock | Directly | 38,300 | $7.70 | $295K | 3.4% | Form 4, Oct 1, 2026 |
Share counts are the amounts Richard A. Heyman reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Richard A. Heyman's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN Common Stock | Through RAHD Capital LLC Held by a company or fund the insider manages | 25,545 | $46.41 | $1.2M | — | Form 4, Feb 17, 2026 |
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Sold | ORIC | 3,500 | $12.91 | $45K | View |
| Oct 1, 2026 | Sold | ORIC | 3,200 | $12.91 | $41K | View |
| Jul 24, 2026 | Sold | ORIC | 7,000 | $12.02 | $84K | View |
| Jul 24, 2026 | Sold | ORIC | 6,100 | $12.02 | $73K | View |
| Jul 6, 2026 | Sold | ORIC | 300 | $12.00 | $4K | View |
| Feb 17, 2026 | Sold | ELVN | 1,230 | $26.18 | $32K | View |
| Jan 20, 2026 | Sold | ELVN | 512 | $26.46 | $14K | View |
| Jan 20, 2026 | Sold | ELVN | 718 | $26.96 | $19K | View |
| Jan 16, 2026 | Sold | ORIC | 3,200 | $12.00 | $38K | View |
| Jan 16, 2026 | Sold | ORIC | 3,500 | $12.00 | $42K | View |
| Jan 9, 2026 | Sold | ELVN | 4,285 | $25.00 | $107K | View |
| Jan 8, 2026 | Sold | ELVN | 8,015 | $25.04 | $201K | View |
| Jan 8, 2026 | Sold | ELVN | 1,620 | $25.00 | $41K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 9776 | Cynthia T Jamison Director, Tractor Supply. Raleigh, NC | $8.7M |
| 9777 | Caton Frates Sr. Executive Vice President, Costco Wholesale. Issaquah, WA | $8.7M |
| 9778 | Jeffry M. Householder President & CEO, Chesapeake Utilities. Dover, DE | $8.7M |
| 9779 | Richard A. Heyman Director, Enliven Therapeutics. South San Francisco, CA | $8.7M |
| 9780 | Shikhar Ghosh Director, WEX. Portland, ME | $8.7M |
| 9781 | Robert Lonergan EVP, CSTO, Assurant. Atlanta, GA | $8.7M |
| 9782 | Richard Pulik CFO, Roivant Sciences | $8.7M |
Other Enliven Therapeutics insiders
All ELVN insiders- Mark Chin$109MDirector. #1387 overall
- Joseph P. Lyssikatos$81.3MCHIEF SCIENTIFIC OFFICER. #1764 overall
- Samuel Kintz$41.3MPRESIDENT AND CEO. #2925 overall
- Anish Patel$10.9MCHIEF OPERATING OFFICER. #8209 overall
- Braden M Leonard$10.7M10% owner. #7717 overall
- David M. Mott$10.6MDirector. #4907 overall
Questions
How much stock does Richard A. Heyman own?
Richard A. Heyman holds $8,652,356 in listed stock based on SEC filings and current prices, mostly Enliven Therapeutics (ELVN). That ranks 9779th on the Stock Rich List.
Is this Richard A. Heyman's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Richard A. Heyman last buy or sell stock?
The most recent open-market trade on file is a sale of 3,500 ORIC shares on Oct 1, 2026 at $12.91.